Form 4: Catalyst Pharmaceuticals CEO Richard Daly Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Catalyst Pharmaceuticals CEO Richard Daly was granted stock options and restricted stock units, increasing his beneficial ownership in the company.
Summary
- Richard Daly, the President and CEO of Catalyst Pharmaceuticals, acquired 491,160 stock options with an exercise price of $21.12 on November 21, 2024.
- These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
- Daly also acquired 60,019 restricted stock units (RSUs) on the same date, which will convert to common stock upon vesting.
- Following these transactions, Daly's total direct holdings include 2,222,172 options and 2,282,191 RSUs.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The grant of stock options and RSUs to the CEO aligns his interests with those of the shareholders.
- The vesting schedule of the options and RSUs encourages long-term performance and commitment from the CEO.
Industry Context
This is a standard practice for executive compensation in publicly traded companies, aligning management's interests with those of shareholders through equity-based incentives.
Comparison to Industry Standards
- Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, used by companies like Amgen, Biogen, and Gilead Sciences.
- The vesting schedule of three years is also typical, encouraging long-term commitment from executives.
- The size of the grant is within the range of what is seen for CEOs of similar sized companies.
Stakeholder Impact
- Shareholders may view this positively as it aligns the CEO's interests with the company's long-term performance.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 11/21/2024 | Date of the stock option and restricted stock unit grants. |
| 11/21/2025 | First vesting date for 1/3rd of the stock options. |
| 11/21/2026 | Second vesting date for 1/3rd of the stock options. |
| 11/21/2027 | Final vesting date for 1/3rd of the stock options. |
| 11/25/2024 | Date the form was signed. |
Keywords
stock options, restricted stock units, insider trading, beneficial ownership, executive compensation, Catalyst Pharmaceuticals, CPRX, Richard Daly
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.